See more : Alpine 4 Holdings, Inc. (ALPP) Income Statement Analysis – Financial Results
Complete financial analysis of PsyBio Therapeutics Corp. (PSYB.V) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PsyBio Therapeutics Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Relief Therapeutics Holding AG (RLFTF) Income Statement Analysis – Financial Results
- High Energy Batteries (India) Limited (HIGHENE.BO) Income Statement Analysis – Financial Results
- The Trendlines Group Ltd. (TRNGF) Income Statement Analysis – Financial Results
- Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) Income Statement Analysis – Financial Results
- Serabi Gold plc (SBI.TO) Income Statement Analysis – Financial Results
PsyBio Therapeutics Corp. (PSYB.V)
About PsyBio Therapeutics Corp.
PsyBio Therapeutics Corp., a biotechnology company, focuses on the research, development, and commercialization of psychedelic-inspired regulated medicines for the treatment of mental health and other disorders in the United States. The company is headquartered in Coconut Creek, Florida.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 50.00K | 62.50K | 1.53M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -50.00K | -62.50K | -1.53M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 390.14K | 622.80K | 54.55K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 3.95M | 8.90M | 991.94K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 3.85K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.95M | 8.90M | 4.85M | 38.97K | 20.86K | 39.85K | 77.04K |
| Other Expenses | 28.11K | 89.65K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 4.41M | 9.61M | 4.90M | 38.97K | 20.86K | 39.85K | 77.04K |
| Cost & Expenses | 4.55M | 9.67M | 6.44M | 38.97K | 20.86K | 39.85K | 77.04K |
| Interest Income | 6.56K | 31.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 21.05K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 146.05K | 9.04M | 6.44M | 171.86K | 161.14K | 0.00 | 0.00 |
| EBITDA | -4.53M | 0.00 | 0.00 | -16.16K | -20.86K | -39.85K | -77.04K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -4.55M | -8.23M | -6.44M | -38.97K | -20.86K | -39.85K | -77.04K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -331.34K | -1.98M | 353.00 | 22.81K | -1.00 | -3.00 | 20.18K |
| Income Before Tax | -4.89M | -11.02M | -6.44M | -16.16K | -20.86K | -39.85K | -56.86K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.43M | 0.35 | -171.86K | -161.14K | 0.00 | 0.00 |
| Net Income | -4.89M | -11.02M | -6.44M | -16.16K | -20.86K | -39.85K | -56.86K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.04 | -0.10 | -0.20 | 0.00 | -0.01 | -0.02 | -0.04 |
| EPS Diluted | -0.04 | -0.10 | -0.20 | 0.00 | -0.01 | -0.02 | -0.04 |
| Weighted Avg Shares Out | 111.81M | 106.94M | 31.59M | 0.00 | 2.36M | 2.33M | 1.44M |
| Weighted Avg Shares Out (Dil) | 111.81M | 106.94M | 31.59M | 0.00 | 2.36M | 2.33M | 1.44M |
No news found for: PSYB.V
Source: https://incomestatements.info
Category: Stock Reports